AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18088035
Drug: Continuous physical
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous physical training (4 to 5 times weekly for 6 months)
Trial: 15571617
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy
Trial: 12206448
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupropion SR 300 mg/day (150 mg b.i.d.)
Trial: 9405728
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist treatment for 6 months
Trial: 8949572
Drug: Intravenous GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GH infusion (0.03 microgram (0.1 mU/kg/min) for 39 hours)
Trial: 8949572
Drug: Subcutaneous GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous GH infusion (0.03 microgram (0.1 mU/kg/min) for 39 hours)
Trial: 8949572
Drug: Intravenous GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GH infusion
Trial: 8949572
Drug: Subcutaneous GH
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous GH infusion
Trial: 8949572
Drug: GH administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GH administration (both routes)
Trial: 8949572
Drug: Both routes
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both routes of GH administration
Trial: 1672803
Drug: atracurium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atracurium 0.6 mg.kg‐1
Trial: 1672803
Drug: half‐dose combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: half‐dose combinations of atracurium and vecuronium
Trial: 1672803
Drug: quarter‐dose combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: quarter‐dose combinations of atracurium and vecuronium
Trial: 1672803
Drug: full‐dose combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: full‐dose combinations of atracurium and vecuronium
Trial: 7043395
Drug: Piribedil (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piribedil (0.1 mg/kg over 30 minutes)
Trial: 7043395
Drug: Domperidone (prior
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone (prior administration)
Trial: 27716691
Drug: Dexmedetomidine 1
RxNorm normalized name: DEXMEDETOMIDINE 120MCG SUBLINGUAL FILM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine 1 mcg/kg IV over 20 min followed by 0.5 mcg/kg/h for 72 h postoperative
Trial: 27716691
Drug: Amiodarone 5
RxNorm normalized name: amiodarone 50 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone 5 mg/kg IV over 20 min followed by 10-15 mcg/kg/h for 72 h postoperative
Trial: 19229114
Drug: Probiotic yogurt
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic yogurt (300 g/day for 6 weeks)
Trial: 19229114
Drug: Ordinary yogurt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary yogurt (300 g/day for 6 weeks)
Trial: 11261907
Drug: Ketamine 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.3 mg/kg and 2% lignocaine infiltration
Trial: 11261907
Drug: Ketamine 0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine 0.9 mg/kg and diazepam 0.07 mg/kg
Trial: 7735519
Drug: Olea europaea
RxNorm normalized name: OLEA EUROPAEA LEAF
DrugBank: Olea europaea leaf (DB14745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olea europaea pollen extract (immunotherapy)
Trial: 1684178
Drug: Broxaterol patch
RxNorm normalized name: procaterol
DrugBank: Procaterol (DB01366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broxaterol patch (size = 1.75 cm2; programmed delivery = 105 mcg/h)
Trial: 6819891
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition (TPN) with constant infusion of hypertonic glucose and amino acids by central vein (35 kcal/kg/day)
Trial: 23863050
Drug: Radium-223 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radium-223 (50 kBq/kg IV, six injections every 4 weeks)
Trial: 23863050
Drug: Placebo (matching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (matching injections every 4 weeks)
Trial: 22101697
Drug: Xinfeng capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng capsule (XFC), 3 capsules, thrice a day for 30 days (2 courses)
Trial: 22101697
Drug: Fengshi gutong
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fengshi gutong capsule (FSGTC), 4 capsules, twice a day for 30 days (2 courses)
Trial: 26591677
Drug: Xinfeng capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xinfeng capsule (XFC)
Trial: 15361940
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate (GM) at 1 mg/kg/hour for 5 days or longer
Trial: 9673806
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy (PT) as an adjunct treatment
Trial: 3149884
Drug: Topical mupirocin
RxNorm normalized name: mupirocin Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical mupirocin (3 daily applications for 8 days)
Trial: 3149884
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin ethylsuccinate (40 mg/kg/day divided into four doses for 8 days)
Trial: 25515106
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I) - single 60-70 minute session with self-help pamphlet (n = 20)
Trial: 25623312
Drug: Pectin (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pectin (24 g/d for 4 weeks)
Trial: 18358071
Drug: 300 mg/day
RxNorm normalized name: alpelisib 300 mg/day (150 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/day SDG
Trial: 18358071
Drug: 600 mg/day
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/day SDG
Trial: 18358071
Drug: 0 mg/day
RxNorm normalized name: RibaTab 800 mg/day Compliance Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/day SDG (placebo)
Trial: 17302251
Drug: Ritonavir-boosted low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ritonavir-boosted low-dose indinavir (200 mg twice daily) and lamivudine (150 mg twice daily)
Trial: 17302251
Drug: Ritonavir-boosted low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ritonavir-boosted low-dose indinavir and lamivudine
Trial: 12957192
Drug: Enfuvirtide (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (90 mg twice daily) at injection site: abdomen
Trial: 12957192
Drug: Enfuvirtide (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (90 mg twice daily) at injection site: thigh
Trial: 12957192
Drug: Enfuvirtide (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (90 mg twice daily) at injection site: arm
Trial: 12957192
Drug: Enfuvirtide (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enfuvirtide (90 mg twice daily)
Trial: 9437183
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (4 g daily equivalent to 0.91 g n‐3 VLCPUFA)
Trial: 4036847
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg cholesterol daily
Trial: 4036847
Drug: 750 mg
RxNorm normalized name: bran 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg cholesterol daily
Trial: 4036847
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg cholesterol daily
Trial: 4036847
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg cholesterol daily (healthy women)
Trial: 4036847
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg cholesterol daily (healthy women)
Trial: 20977087
Drug: RMK (0.25%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RMK (0.25% ropivacaine, morphine 0.2 mg/mL, ketorolac 1 mg/mL)
Trial: 12358160
Drug: Carbamazepine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (400 mg) - Test formulation
Trial: 12358160
Drug: Carbamazepine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (400 mg) - Reference formulation
Trial: 7488279
Drug: CAMPATH‐1H (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAMPATH‐1H (1, 3, 10, 30, 60, and 100 mg)
Trial: 2297656
Drug: 6-hour continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-hour continuous infusion of doxorubicin
Trial: 2297656
Drug: Standard rapid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard rapid infusion of doxorubicin (15 to 20 minutes)
Trial: 2297656
Drug: Standard rapid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard rapid infusion of doxorubicin
Trial: 7348120
Drug: Pentazocine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (1 mg/kg)
Trial: 7348120
Drug: No opiate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No opiate antagonists
Trial: 23708746
Drug: Gabapentin generic
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin generic formulations (three generic formulations)
Trial: 23708746
Drug: Branded formulation
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded formulation of gabapentin
Trial: 21062906
Drug: Certain medications
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Certain medications
Trial: 17244243
Drug: 1 unit/ml
RxNorm normalized name: vasopressin 1 unit/mL-D5% intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 unit/ml of heparin saline
Trial: 17244243
Drug: 10 units/ml
RxNorm normalized name: heparin 10 units/mL injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 units/ml of heparin saline
Trial: 12647460
Drug: Day hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day hospital treatment for acute psychiatric patients
Trial: 8605897
Drug: Ceftriaxone 1
RxNorm normalized name: ceftriaxone 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 1 g/day
Trial: 2897008
Drug: Ceftriaxone 2
RxNorm normalized name: ceftriaxone 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone 2 g/day
Trial: 2665059
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (25 U fast-acting insulin bolus followed by continuous infusion of 1 U/kg b.w. for 1 hour)
Trial: 23709323
Drug: Crushed MSN
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crushed MSN (≥60/2.4 mg)
Trial: 9301462
Drug: Amifostine (910
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amifostine (910 mg/m2) before cyclophosphamide (1500 mg/m2) for two cycles
Trial: 3434998
Drug: Standardized aggressive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized aggressive treatment including wide resection, adjuvant radio- or chemotherapy and management of advanced disease
Trial: 3434998
Drug: Adjuvant cytostatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant cytostatic therapy in patients with colonic tumours of Dukes B and C stages
Trial: 3434998
Drug: Irradiation followed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Irradiation followed by attempted curative surgery in primarily inoperable rectal cancer
Trial: 19329546
Drug: 300 mg/74
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg/74 mg BZP/TFMPP
Trial: 19329546
Drug: 57.6 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 57.6 g (6 units) alcohol
Trial: 18622632
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1200 mg/m(2) per day (n = 12)
Trial: 18622632
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CsA) 4-5 mg/kg per day (n = 12)
Trial: 15882244
Drug: Lansoprazole, amoxicillin
RxNorm normalized name: lansoprazole, amoxicillin and levofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole, amoxicillin and clarithromycin (antibiotic group)
Trial: 15882244
Drug: Lansoprazole and
RxNorm normalized name: Lansoprazole and naproxen only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole and identical antibiotic placebos (control group)
Trial: 8843174
Drug: Parenteral fish
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral fish oil (FO) at 0.15 g/kg/d for 5 days
Trial: 8843174
Drug: Soybean oil
RxNorm normalized name: Soybean Oil
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soybean oil (SO) at 1.0 g/kg/d for 5 days
Trial: 1509577
Drug: Foot zone
RxNorm normalized name: Na-zone
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Foot zone therapy (10 sessions of 1 hour each at intervals of one week)
Trial: 1509577
Drug: Uniform clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uniform clinical care without placebo foot zone therapy
Trial: 6373340
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (100 mg orally)
Trial: 29789243
Drug: MenACWY-TT and
RxNorm normalized name: meningococcal conjugate quadrivalent, MenACWY-TT (MCV4)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-TT and AS04-HPV16/18 co-administered
Trial: 29789243
Drug: MenACWY-TT, AS04-HPV16/18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MenACWY-TT, AS04-HPV16/18 and Tdap co-administered
Trial: 29789243
Drug: Tdap and
RxNorm normalized name: metformin and ertugliflozin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap and AS04-HPV16/18 co-administered
Trial: 18349394
Drug: Irinotecan/FU/FA combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irinotecan/FU/FA combination therapy
Trial: 11498702
Drug: Cefepime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime (2 g every 8 or 12 hours)
Trial: 9065256
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin prophylaxis (fractionated or unfractionated)
Trial: 6881119
Drug: Bromocriptine 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 15 mg/day plus cleansing enemas
Trial: 6881119
Drug: Bromocriptine 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine 30 mg/day plus cleansing enemas
Trial: 6881119
Drug: Neomycin 6
RxNorm normalized name: neomycin 65000 UNT/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin 6 g/day plus cleansing enemas (standard therapy)
Trial: 30672248
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) treatment at Baihui (GV 20), Fengfu (GV 16), Shenting (GV 24), Taiyang (EX‐HN 5), Shangyintang (Extra 3), Dazhong (KI 14); EA applied at Taiyang (EX‐HN 5), Baihui (GV 20), Shenting (GV 24) with dilatational wave, 10 Hz/50 Hz frequency, 0.5 to 5.0 mA intensity, once every two days, three treatments per week for 12 weeks.
Trial: 30672248
Drug: Donepezil hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil hydrochloride tablets, once a day before sleep for 12 weeks.
Trial: 30672248
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups evaluated at baseline, 12 weeks, and 24 weeks after treatment.
Trial: 28230390
Drug: Deprexis (Internet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deprexis (Internet treatment for depression) for 8 weeks
Trial: 1398561
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of diethylstilbestrol
Trial: 2993946
Drug: ACTH 4‐9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH 4‐9 analogue (ORG 2766), 80 mg daily during 14‐28 days
Trial: 20191360
Drug: Taranabant 2-8
RxNorm normalized name: Taranabant
DrugBank: Taranabant (DB06624)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taranabant 2-8 mg
Trial: 20837597
Drug: Nucleotide-supplemented formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleotide-supplemented formula (31 mg/L)
Trial: 12380632
Drug: Glyburide/metformin 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide/metformin 1.25 mg/250 mg tablets BID for HbA1c < 9%; Glyburide/metformin 2.5 mg/500 mg tablets BID for HbA1c >= 9%.
Trial: 12380632
Drug: Glyburide/metformin tablets.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide/metformin tablets.
Trial: 1769141
Drug: Preparation A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation A: rhEPO 2000 IU in 1 ml (Cilag)
Trial: 1769141
Drug: Preparation B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation B: rhEPO 2000 IU in 1 ml (Boehringer Mannheim)
Trial: 1769141
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline 1 ml (placebo)
Trial: 28081945
Drug: Fluocinolone Acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone Acetonide (FAc) 0.2 μg/day
Trial: 28081945
Drug: Fluocinolone Acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone Acetonide (FAc) 0.5 μg/day
Trial: 28081945
Drug: Fluocinolone Acetonide
RxNorm normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluocinolone Acetonide (FAc) 0.2 μg/day and 0.5 μg/day
Trial: 23463655
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 (all doses)
Trial: 10437863
Drug: Control (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (placebo plus conventional antihypertensive therapy)
Trial: 7767512
Drug: Inhaled beclomethasone
RxNorm normalized name: beclomethasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled beclomethasone dipropionate (BDP) 400 micrograms/day for 7 months
Trial: 6104610
Drug: H1 antihistamine
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 antihistamine (chlorpheniramine)
Trial: 6104610
Drug: H2 antihistamines
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 antihistamines
Trial: 30554141
Drug: Treatment response
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment response
Trial: 30741025
Drug: Shen Cao
RxNorm normalized name: Ren shen
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shen Cao granules (10 g once daily)
Trial: 28937980
Drug: Probiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic mixture composed of five Lactobacilli strains and two Bifidobacteria strains, administered once a day for 60 days
Trial: 3307386
Drug: Monocomponent pertussis
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monocomponent pertussis toxoid vaccine (JNIH‐7)
Trial: 3307386
Drug: Two-component vaccine
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-component vaccine (JNIH‐6)
Trial: 30326609
Drug: Micronutrient Powders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient Powders (MNP) with low iron dose (6 mg/serving)
Trial: 22606361
Drug: Low plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low plasma ferritin (<30 µg/L)
Trial: 22606361
Drug: Low plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low plasma ferritin (<30 µg/L) among HIV-infected patients